Pfizer (PFE) Osake Kurssi
Pfizer Kurssi
Viimeisten 19 vuoden aikana Pfizern liikevaihto kasvoi 1,4 % vuodessa ja ylsi 62,58 Mrd. USD:een. Osakekohtainen tulos on laskenut 0,6 % vuodessa viimeisten 19 vuoden aikana. Pfizern nettomarginaali 12,4 % on laskenut verrattuna 27,2 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 6,29 %. Jakosuhde on noin 126 % tuloksesta. Osinko on kasvanut 3,1 % vuodessa viimeisten 19 vuoden aikana. Pfizern 12 kuukauden konsensustavoitehinta on 27,00 USD, noin ali kurssia 1,3 %. 36 analyytikosta 14 suosittaa ostoa — kokonaiskonsensus on Pidä.
Pfizer osakekurssi
Pfizer liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Pfizer -osakkeesta
Pfizer Inc's business model is focused on pharmaceutical research, development, manufacturing, and sales. The company operates in various therapeutic areas, including but not limited to oncology, cardiovascular, immunology, and neurology. Pfizer's mission is to discover and develop innovative medicines that enhance the health and well-being of people worldwide. With a diverse portfolio of prescription medicines, vaccines, and consumer healthcare products, Pfizer strives to improve patient outcomes and provide effective healthcare solutions. Through strategic partnerships and collaborations, Pfizer continues to invest in research and development to address unmet medical needs and drive sustainable growth in the pharmaceutical industry.
Pfizer Inc is primarily active in the pharmaceutical industry.
The main competitors of Pfizer Inc in the market include pharmaceutical companies such as Johnson & Johnson, Novartis AG, Merck & Co., Inc., and GlaxoSmithKline plc.
Pfizer Inc. is a renowned pharmaceutical giant with a rich history and influential background. Established in 1849, Pfizer has evolved into one of the largest global pharmaceutical companies. Headquartered in New York City, Pfizer has played a pivotal role in the healthcare industry's advancement. The company is committed to developing innovative medicines and vaccines that improve and save lives worldwide. With its vast expertise, extensive research and development efforts, and strategic collaborations, Pfizer has introduced groundbreaking treatments for various diseases. As a leader in the pharmaceutical sector, Pfizer continues to prioritize delivering transformative healthcare solutions to address the evolving needs of patients and healthcare professionals.
Pfizer Inc has achieved significant milestones throughout its history. Founded in 1849, the company has become one of the world's leading pharmaceutical corporations. Notably, Pfizer developed and marketed groundbreaking drugs that have revolutionized medical treatments. In 1998, the company gained immense recognition with the introduction of Viagra, a medication for erectile dysfunction. Pfizer's research and innovation also led to the development of Lipitor, a cholesterol-lowering drug that became the best-selling prescription medicine worldwide. Furthermore, Pfizer remains dedicated to advancing healthcare by continuously expanding its product portfolio and pursuing collaborations to address unmet medical needs. With its rich history and commitment to innovation, Pfizer Inc continues to make significant contributions to the healthcare industry.
Pfizer Inc is primarily present in various countries and regions across the globe. The company has a widespread presence with operations in multiple key markets. Pfizer's global presence includes major countries such as the United States, United Kingdom, Germany, Japan, China, India, Brazil, and many more. With a diverse international footprint, Pfizer Inc continues to serve patients and healthcare professionals worldwide by delivering innovative healthcare solutions and medications.
Pfizer Inc, a renowned pharmaceutical company, represents values of integrity, excellence, and patient-centricity. With a strong corporate philosophy, Pfizer aims to improve the health and well-being of individuals worldwide through innovative medicines and therapies. Committed to scientific advancement, Pfizer provides quality healthcare solutions while upholding ethical practices. Through extensive research and development, they strive to discover and deliver life-saving and life-enhancing treatments. As a global leader in the healthcare industry, Pfizer's dedication to patient care, scientific ingenuity, and ethical principles are fundamental to their corporate philosophy and drive their mission to revolutionize healthcare for a better tomorrow.
Analyytikot asettavat tällä hetkellä Pfizer-osakkeelle keskimääräisen tavoitehinnan 27,38 USD (mediaani: 27,00 USD), mikä merkitsee +0,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 36 analyytikkoarvioon.
36 analyytikkoa arvioi tällä hetkellä Pfizer-osaketta: 14 suosittaa ostoa, 20 pitoa ja 2 myyntiä. Vuodelle 2026 analyytikot odottavat Pfizer-yhtiöltä 62,25 Mrd. USD liikevaihtoa ja 2,99 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Pfizer-osake noteerataan hintaan 24,41 EUR (27,36 USD).
Pfizer-osake (PFE) on listattuna 13 pörssissä, muun muassa: NYSE (PFE), London (0Q1N.L), SIX (Zürich) (PFE.SW), XETRA (PFE.DE), Frankfurt (PFE.F), München (PFE.MU), Stuttgart (PFE.SG), Düsseldorf (PFE.DU).
Pfizer Inc is a multinational pharmaceutical company headquartered in New York City. The company operates in the research, development, production, and distribution of drugs. Pfizer is one of the largest pharmaceutical companies in the world. In this article, we will describe the business model of Pfizer Inc. Divisions Pfizer has divided its business operations into three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. Biopharmaceuticals The Biopharmaceuticals division focuses on the research and development of drugs. The goal is to develop new drugs and therapies that meet the needs of patients. Research and development are focused on various areas such as oncology, cardiovascular, immunological, and neuroscience disorders. Pfizer has a strong pipeline with numerous drugs in late-stage clinical development. An example is the drug Tofacitinib, which is used to treat rheumatoid arthritis. In 2020, Pfizer generated revenue of $51.8 billion in this division. Beyond the Baby Cure The Beyond the Baby Cure division refers to products that are not drug-based. This includes products like vitamin-rich dietary supplements, pain relievers, condoms, and personal care products. Pfizer acquired Wyeth in 2006, a company active in this segment. This allowed Pfizer to expand its product portfolio. In 2020, Pfizer generated revenue of $2.5 billion in this segment. Contract Manufacturing Pfizer's Contract Manufacturing division refers to the production of drugs for other companies. The company offers services for the entire value chain, from drug manufacturing to logistics. In 2020, Pfizer generated revenue of $2.2 billion in this division. Products Pfizer offers a wide range of products covering various areas. Here are some of Pfizer's key products: - Viagra, a medication for the treatment of erectile dysfunction - Lyrica, a medication for the treatment of neuropathic pain - Prevnar, a vaccine for the prevention of pneumococcal infections - Xeljanz, a medication for the treatment of rheumatoid arthritis - Lipitor, a medication for lowering cholesterol levels Conclusion Pfizer is a leading pharmaceutical company with a broad portfolio of products and services. The company specializes in three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. With a strong commitment to research and development and an impressive pipeline, Pfizer has a strong position in the industry.
odotettu liikevaihto Pfizer on 62,25 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Pfizer on 16,99 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Pfizer:n hinta-voitto-suhde (P/E) on tällä hetkellä 9,16. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Pfizer-osakkeen arvostusta.
Pfizer:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,50. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Pfizer-osakkeen arvostuskennuslukuna.
Pfizer:n Eulpool-laatuscore on 1/10.
Pfizer:n ISIN on US7170811035. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Pfizer:n WKN on 852009. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Pfizer:n ticker on PFE. Tämä pörssinoteeraus käytetään Pfizer-osakkeiden kauppaan pörssissä.
Pfizer osake
Pfizer vertaisryhmä
Pfizer Ticker
Pfizer FIGI
Kaikki tunnusluvut ja syvällinen analyysi Pfizer:sta
Meidän osakeanalyysimme Pfizer-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Pfizer:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: